Table 3 Patients’ characteristics association with the cf-nDNA and the relative cf-mtDNA (cf-ND1/cf-β-globin ratio) levels in individual human follicular fluid
Variable | Mean | n (%) | Min-Max | SD | cf-nDNA | relative cf-mtDNA | ||
|---|---|---|---|---|---|---|---|---|
β ± SE | p | β ± SE | p | |||||
Age (years) | 32.13 | 225 (100) | 21–45 | 4.85 | −0.034 ± 0.03 | 0.25 | 0.22 ± 0.085 | 0.009 |
BMI (kg/m2) | 22.38 | 225 (100) | 16.6–33.9 | 3.58 | 0.069 ± 0.044 | 0.12 | −0.15 ± 0.13 | 0.25 |
AMH (ng/ml) | 3.37 | 219 (97.3) | 0.33–8.67 | 1.99 | 0.0007 ± 0.075 | 0.70 | 0 ± 0.20 | 0.89 |
Basal FSH (IU/L) | 7.49 | 225 (100) | 1.79–17.52 | 2.60 | 0.025 ± 0.057 | 0.66 | −0.27 ± 0.16 | 0.09 |
Basal LH (IU/L) | 4.45 | 225 (100) | 0.51–21.41 | 2.49 | 0.001 ± 0.059 | 0.25 | 0.016 ± 0.17 | 0.61 |
Basal E2 (pg/ml) | 43.56 | 225 (100) | 6–299.8 | 39.24 | 0 ± 0.004 | 0.88 | 0.006 ± 0.010 | 0.26 |
Antral follicle count | 17.48 | 225 (100) | 3–40 | 7.84 | 0.026 ± 0.017 | 0.012 | −0.050 ± 0.053 | 0.34 |
Days of stimulation | 9.75 | 225 (100) | 3–22 | 2.74 | −0.019 ± 0.05 | 0.039 | 0.0023 ± 0.15 | 0.48 |
Total dose of gonadotropins (IU) | 2089.69 | 225 (100) | 225–6800 | 835.12 | −0.027 ± 0.0002 | 0.015 | 0.0014 ± 0.0005 | 0.58 |
Ultra-long protocol | – | 97 (43.11) | – | – |  |  |  | ref |
Long protocol | – | 17 (7.56) | – | – | 0.054 ± 0.57 | 0.96 | −1.56 ± 1.64 | 0.34 |
Antagonist protocol | – | 71 (31.56) | – | – | 0.17 ± 0.34 | 0.63 | −0.18 ± 0.98 | 0.86 |
PPOS | – | 40 (17.78) | – | – | −0.37 ± 0.41 | 0.36 | 1.33 ± 1.17 | 0.26 |